Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach

Tim J A Dekker, Susan Ter Borg, Gerrit K J Hooijer, Sybren L Meijer, Jelle Wesseling, James E Boers, Ed Schuuring, Jos Bart, Joost van Gorp, Wilma E Mesker, Judith R Kroep, Vincent T H B M Smit, Marc J van de Vijver

    Research output: Contribution to journalArticleAcademicpeer-review

    52 Citations (Scopus)
    247 Downloads (Pure)

    Abstract

    INTRODUCTION: Overexpression of the human epidermal growth factor receptor 2 (HER2) as a result of HER2 gene amplification is associated with a relatively poor prognosis in breast cancer and is predictive of HER2-targeting therapy response. False-positive rates of up to 20% for HER2 testing have been described. HER2-testing laboratories are therefore encouraged to participate in external quality control schemes in order to improve HER2-testing standardization.

    METHODS: This study investigated the feasibility of retesting large numbers of invasive breast cancers for HER2 status on tissue micro-array (TMA) as part of a quality control scheme. For this assessment different HER2 testing methods were used including HER2 detecting antibodies SP3, 4B5, Herceptest and mono color silver in situ hybridization (SISH) and dual color SISH. Final HER2 status for each tumor on the TMA was compared to the local testing result for the same tumor. Discordances between these two results were investigated further by staining whole tumor sections.

    RESULTS: For this study, 1,210 invasive breast carcinomas of patients treated in six hospitals between 2006 and 2008 were evaluated. Results from the three immunohistochemistry (IHC) and two in situ hybridization (ISH) assays performed on the TMAs were compared. The final HER2 status on TMA was determined with SP3, 4B5 and mono color SISH. Concordance between local HER2 test results and TMA retesting was 98.0%. Discordant results between local and TMA retesting were found in 20 tumors (2.0%). False positive HER2 IHC results were identified in 13 (1.3%) tumors; false negative IHC results in seven (0.7%) tumors.

    CONCLUSIONS: Retesting large volumes of HER2 classified breast carcinomas was found to be feasible and can be reliably performed by staining TMAs with SP3, 4B5 and mono color SISH in combination with full-sized slides for discordant cases. The frequency of false-positive results was lower than previously reported in the literature. This method is now offered to other HER2-testing laboratories.

    Original languageEnglish
    Article number93
    Number of pages12
    JournalBreast cancer research
    Volume14
    Issue number3
    DOIs
    Publication statusPublished - 13-Jun-2012

    Keywords

    • IN-SITU HYBRIDIZATION
    • MONOCLONAL-ANTIBODY SP3
    • ADJUVANT CHEMOTHERAPY
    • IMMUNOHISTOCHEMICAL ASSAY
    • TRASTUZUMAB
    • HER-2/NEU
    • PLUS
    • CARCINOMAS
    • OVEREXPRESSION
    • AMPLIFICATION

    Fingerprint

    Dive into the research topics of 'Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach'. Together they form a unique fingerprint.

    Cite this